Document Detail

Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease.
MedLine Citation:
PMID:  7824809     Owner:  NLM     Status:  MEDLINE    
Formoterol, a new beta 2-agonist, and salbutamol were given as aerosols twice and four times daily, respectively, to patients with reversible obstructive lung disease. The study was controlled and double blind, and continued for 12 weeks. Ninety-nine patients from five study centers were included and 89 patients could be properly evaluated. The formoterol-treated patients used significantly less rescue medicine (salbutamol aerosol) and had higher morning PEF values. For the other efficacy variables (daytime FEV1.0, evening PEF, patient and investigator global evaluations, night sleeping time) and tolerance (side effects noted by patients, blood and urine laboratory values, ECG, patient and investigator global evaluation), there were no significant differences between the formoterol- and the salbutamol-treated groups.
G Stålenheim; T Wegener; L Grettve; B Lundbäck; B Melander; K Osterman; E Piitulainen; O Zetterström
Related Documents :
2653799 - Chronic obstructive pulmonary disease.
20390069 - The site of airway obstruction among patients of emphysema: role of impulse oscillometry.
20830229 - Airway responsiveness to inhaled aspirin is influenced by airway hyperresponsiveness in...
19299889 - Effect of preceding inspiratory speed and end-inspiratory pause on forced expiratory ma...
11587989 - Interleukin-4 and its alternatively spliced variant (il-4delta2) in patients with atopi...
20415049 - Sequential sensitization to different occupational compounds in a young woman.
9692519 - Kartagener's syndrome: a re-visit with chinese perspectives.
18310869 - Evaluation of conner's continuous performance test in hemodialysis patients.
23327059 - Overexpression of c-met in cervical intraepithelial neoplasia.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Respiration; international review of thoracic diseases     Volume:  61     ISSN:  0025-7931     ISO Abbreviation:  Respiration     Publication Date:  1994  
Date Detail:
Created Date:  1995-02-14     Completed Date:  1995-02-14     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  0137356     Medline TA:  Respiration     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  305-9     Citation Subset:  IM    
Department of Lung Medicine, Akademiska sjukhuset, Uppsala, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Adrenergic beta-Agonists / administration & dosage*,  adverse effects,  therapeutic use
Albuterol / administration & dosage,  adverse effects,  therapeutic use
Double-Blind Method
Ethanolamines / administration & dosage*,  adverse effects,  therapeutic use
Forced Expiratory Volume
Lung Diseases, Obstructive / drug therapy*,  physiopathology
Middle Aged
Peak Expiratory Flow Rate
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Ethanolamines; 18559-94-9/Albuterol; 5ZZ84GCW8B/formoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Which steps in lymphocyte recirculation are regulated by interferon-gamma?
Next Document:  Severe exacerbations of chronic obstructive pulmonary disease treated with BiPAP by nasal mask.